Abstract
The objective of this study is to determine whether pergolide therapy is an effective modality for the de novo treatment of patients with macroprolactinomas. Twenty-two consecutive patients with macroprolactinomas were included in the study and followed prospectively. These included 16 men and 6 women in whom pregnancy was not of concern. Pergolide was administered once or twice a day depending on the patient's preference. Ten patients received 0.1 mg daily as a maintenance regimen and in the others the daily dose ranged from 0.05 to 0.5 mg. Eight patients reported minor but tolerable side effects. One patient had to be switched to cabergoline because of intolerable nausea. After a mean of 12 months (range, 3–36), mean PRL levels declined from 3,135 ng/ml (range, 126–31,513) to 50 ng/ml (3–573), representing a mean PRL suppression of 88% (range, 0–99). PRL levels became normal in 15 patients and decreased to 25–40 ng/ml in 3 others. The mean tumor volume shrinkage was 25% or greater in 19 patients (86%), 50% or greater in 17 patients (77%), and 75% or greater in 10 patients (45%). Visual abnormalities were reversible after pergolide therapy in all but 1 of 12 patients with initially abnormal formal visual testing. Two out of 4 premenopausal women did not normalize PRL levels and had persistent oligomenorrhea. Testosterone was low in 14 men at presentation and normalized in 3 with pergolide therapy. We conclude that pergolide is a safe, inexpensive, and generally well-tolerated dopamine agonist for the treatment of macroprolactinomas in men and women in whom pregnancy is not of concern. In these specific populations, pergolide may become the first-line therapy for treatment of macroprolactinomas.
Similar content being viewed by others
References
Orrego JJ, Barkan AL. Pituitary disorders. Drug treatment options. Drugs 2000;59:93–106.
Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992;13:220–240.
Molitch ME. Medical treatment of prolactinomas. Endocrinol Metab Clin North Am 1999;28:143–169.
Molitch ME. Pathologic hyperprolactinemia. Endocrinol Metab Clin North Am 1992;21:877–901.
Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group [see comments]. N Engl J Med 1994;331:904–909.
Ferrari CI, Abs R, Bevan JS, et al. Treatment of macroprolactinoma with cabergoline: A study of 85 patients. Clin Endocrinol (Oxf) 1997;46:409–413.
Biller BM, Molitch ME, Vance ML, et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996;81: 2338–2343.
Colao A, Di Sarno A, Landi ML, et al. Long-term and lowdose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 1997;82:3574–3579.
Pontikides N KG, Nikopoulou E, Kaltsas T. Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas. Pituitary 2000;2:277–2781.
Lemberger L, Crabtree RE. Pharmacologic effects in man of a potent, long-acting dopamine receptor agonist. Science 1979;205:1151–1153.
Franks S, Horrocks PM, Lynch SS, Butt WR, London DR. Treatment of hyperprolactinaemia with pergolide mesylate: Acute effects and preliminary evaluation of long-term treatment. Lancet 1981;2:659–661.
Kendall-Taylor P, Hall K, Johnston DG, Prescott RW. Reduction in size of prolactin-secreting tumours in men treated with pergolide. Br Med J (Clin Res Ed) 1982;285:465–467.
Blackwell RE, Bradley EL, Jr., Kline LB, et al. Comparison of dopamine agonists in the treatment of hyperprolactinemic syndromes: A multicenter study. Fertil Steril 1983;39: 744–748.
Kleinberg DL, Boyd AEd, Wardlaw S, et al. Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. N Engl J Med 1983;309:704–709.
Kletzky OA, Borenstein R, Mileikowsky GN. Pergolide and bromocriptine for the treatment of patients with hyperprolactinemia. Am J Obstet Gynecol 1986;154:431–435.
Berezin M, Avidan D, Baron E. Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs. Isr J Med Sci 1991; 27:375–379.
Lamberts SW, Quik RF. A comparison of the ef~cacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia. J Clin Endocrinol Metab 1991;72:635–641.
Freda PU, Andreadis CI, Khandji AG, et al. Long-term treatment of prolactin-secreting macroadenomas with pergolide. J Clin Endocrinol Metab 2000;85:8–13.
Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients [see comments]. J Clin Endocrinol Metab 1999;84:2518–2522.
Ferrari C, Paracchi A, Mattei AM, de Vincentiis S, D'Alberton A, Crosignani P. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol(Copenh) 1992;126:489–494.
Molitch ME, Elton RL, Blackwell RE, et al. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: Results of a prospective multicenter study. J Clin Endocrinol Metab 1985;60:698–705.
De Rosa M, Colao A, Di Sarno A, et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: A comparison with bromocriptine. Eur J Endocrinol 1998;138:286–293.
Perryman RL, Rogol AD, Kaiser DL, MacLeod RM, Thorner MO. Pergolide mesylate: Its effects on circulating anterior pituitary hormones in man. J Clin Endocrinol Metab 1981;53:772–778.
Martin WH, Rogol AD, Kaiser DL, Thorner MO. Dopaminergic mechanisms and luteinizing hormone (LH) secretion. II. Differential effects of dopamine and bromocriptine on LH release in normal women. J Clin Endocrinol Metab 1981;52:650–656.
Molitch ME. Pregnancy and the hyperprolactinemic woman. N Engl J Med 1985;312:1364–1370.
Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative cabergoline. Reprod Toxicol 1996;10:333–337.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Orrego, J.J., Chandler, W.F. & Barkan, A.L. Pergolide As Primary Therapy for Macroprolactinomas. Pituitary 3, 251–256 (2000). https://doi.org/10.1023/A:1012836331506
Issue Date:
DOI: https://doi.org/10.1023/A:1012836331506